URGN logo

URGN
UroGen Pharma Ltd

2,280
Mkt Cap
$1.41B
Volume
364,372.00
52W High
$32.37
52W Low
$3.61
PE Ratio
-10.49
URGN Fundamentals
Price
$28.89
Prev Close
$29.88
Open
$29.84
50D MA
$22.89
Beta
1.10
Avg. Volume
772,253.02
EPS (Annual)
-$3.19
P/B
-11.33
Rev/Employee
$377,278.35
$1,135.16
Loading...
Loading...
News
all
press releases
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
News Placeholder
More News
News Placeholder
Urogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Urogen Pharma (NASDAQ:URGN - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analyst...
News Placeholder
Urogen Pharma (NASDAQ:URGN) Trading Up 14% on Better-Than-Expected Earnings
Urogen Pharma (NASDAQ:URGN) Trading 14% Higher Following Better-Than-Expected Earnings...
News Placeholder
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of +16.44% and +16.96%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +16.13% and +14.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Wednesday
Urogen Pharma (NASDAQ:URGN) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-urogen-pharma-ltd-stock...
News Placeholder
IBRX: What Anktiva's Bladder Data Says About 2026 Sales
ImmunityBio heads into 2026 riding Anktiva growth, but upcoming bladder trial data and broader use in earlier care will be key to sustaining momentum.
News Placeholder
HC Wainwright Predicts Urogen Pharma Q1 Earnings
Urogen Pharma (NASDAQ:URGN - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Urogen Pharma in a report issued on Thursday, April...
News Placeholder
Urogen Pharma (NASDAQ:URGN) Rating Increased to Strong-Buy at Jefferies Financial Group
Jefferies Financial Group raised Urogen Pharma to a "strong-buy" rating in a report on Friday...
News Placeholder
Urogen Pharma (NASDAQ:URGN) Trading Up 9% - Should You Buy?
Urogen Pharma (NASDAQ:URGN) Trading 9% Higher - Here's Why...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available